Molecular Typing and Virulence Characteristic of Methicillin-Resistant *Staphylococcus Aureus* Isolates from Pediatric Patients in Bucaramanga, Colombia

Mayra Alejandra Machuca¹, Luis Miguel Sosa², Clara Isabel González¹*

¹Grupo de Inmunología y Epidemiología Molecular, GIEM, Facultad de Salud, Universidad Industrial de Santander, Bucaramanga, Colombia, ²Grupo PAIDOS, Departamento de Pediatría, Hospital Universitario de Santander, Facultad de Salud, Universidad Industrial de Santander, Bucaramanga, Colombia

Abstract

**Background:** *Staphylococcus aureus* is among the most common global nosocomial pathogens. The emergence and spread of methicillin-resistant *Staphylococcus aureus* (MRSA) is a public health problem worldwide that causes nosocomial and community infections. The goals of this study were to establish the clonal complexes (CC) of the isolates of MRSA obtained from pediatric patients in a university hospital in Colombia and to investigate its molecular characteristics based on the virulence genes and the genes of staphylococcal toxins and adhesins.

**Methods:** A total of 53 MRSA isolates from pediatric patients with local or systemic infections were collected. The MRSA isolates were typed based on the SCCmec, MLST, spa and agr genes. The molecular characterization included the detection of Panton-Valentine Leukocidin, superantigenic and exfoliative toxins, and adhesin genes. The correlation between the molecular types identified and the profile of virulence factors was determined for all isolates.

**Results:** Four CC were identified, including CC8, CC5, CC80 and CC78. The ST8-MRSA-IVc-agrI was the predominant clone among the isolates, followed by the ST5-MRSA-I-agrII and ST5-MRSA-Iv-agrII clones. Twelve spa types were identified, of which t10796 and t10799 were new repeat sequences. The isolates were carriers of toxin genes, and hlg (100%), sek (92%) and pvl (88%) were the most frequent. Ten toxin gene profiles were observed, and the most frequent were seq-sek-hlg (22.6%), sek-hlg (22.6%), seq-seq-sek-hlg (18.9%) and sek-sek-hlg (15.1%). The adhesion genes were present in most of the MRSA isolates, including the following: clf-A (89%), clf-B (87%), fnb-A (83%) and ica (83%). The majority of the strains carried SCCmec-IvC and were identified as causing nosocomial infection. No significant association between a molecular type and the virulence factors was found.

**Conclusion:** Four major MRSA clone complexes were identified among the isolates. ST8-MRSA-IVc-agrI pvl+ (USA300-LV) was the most frequent, confirming the presence of community-associated MRSA in Colombian hospitals.

Introduction

*Staphylococcus aureus* is an important cause of a wide variety of diseases, including skin and soft-tissue infections, osteomyelitis, necrotizing pneumonia, bacteremia and endocarditis [1]. The clinical importance of *S. aureus* is attributed to its high virulence and its rapid development of drug resistance. Surface proteins, toxins, and enzymes [2] are virulence factors involved in the infection process.

Since methicillin-resistance *S. aureus* (MRSA) was identified for the first time in 1961, it has become the most common cause of nosocomial and community infection worldwide [3]. Patients with invasive MRSA infections have a higher mortality rate than those with non-invasive MRSA infection or methicillin-sensible *S. aureus* (MSSA) infection [4].

A number of molecular methods have been developed and implemented to type MRSA isolates, including staphylococcal cassette chromosome mecA typing (SCCmec) [5], pulsed-field gel electrophoresis (PFGE) [6], multilocus sequence typing (MLST) [7], spa typing and identification of the accessory gene regulator (agr) [8]. These typing methods have been used to identify the major clones disseminated globally and to monitor the evolutionary process of these pandemic clones. Some of the pandemic clones identified worldwide include the New York/Japan (ST5-MRSA-II), Hungarian (ST239-MRSA-III), Pediatric (ST5-MRSA-IVa) and USA 300 (ST8-MRSA-IVA) clones [9,10]; in Latin America, the Brazilian (ST239-MRSA-III) and Cordobes/ Chileno (ST5-MRSA-IV) clones predominated [11].

MRSA is a growing health problem in Colombian hospitals, in which its prevalence is approximately 40–60% [12,13,14]; few molecular epidemiology analyses have been performed. Previous
studies have focused on MRSA typing using PFGE and SCCmec and have selected a limited number of representative isolates to be analyzed by MLST [15,16]. Several MRSA clones associated with nosocomial infection have been described, including the Pediatric, Brazilian, Chilean and USA-300 clones [15–17]. The USA-300 clone detected in Latin America is a variant (USA-300 LV) that carries the SCCmec IVc; exhibits high resistance to tetracycline and an absence of the arginine catabolic mobile element (ACME); and has been reported as a predominant clone in the 5 major cities of Colombia [17,18]. The Pediatric clone has been detected in a significant percentage of cases, and it has a multi-resistant phenotype with resistance to several non-beta lactam antibiotics such as ciprofloxacin, clindamycin, erythromycin, gentamicin, rifampicin, tetracycline, chloramphenicol and trimethoprim/sulfamethoxazole [16].

MRSA expresses different virulence factors involved in the pathogenesis of *S. aureus* infection. These virulence factors are associated with attachment, persistence, the evasion/destruction of host defenses, tissue invasion/penetration and toxin-mediated disease [19]. The studies mentioned above and others described in Colombia have performed MRSA typing to identify the circulating clonal complex in hospitals, but correlation of the genotype with the phenotype and virulence factors has not been performed. We performed molecular typing using MLST, the *spa* gene, SCCmec and *agr* in a cohort of MRSA isolates obtained from pediatric patients hospitalized in a university hospital from Bucaramanga, Colombia and correlated the molecular clones identified with their phenotypes and virulence factors.

**Materials and Methods**

**Clinical isolates and antimicrobial susceptibility test**

A total of 53 MRSA isolates were collected from pediatric patients with local or systemic infections in a university hospital in Bucaramanga, Colombia from March 2007 to March 2009. All of the isolates were individual cases that were epidemiologically unrelated. MRSA was identified by an automated method (BD PhoenixTM 100, USA) and confirmed by polymerase chain reaction (PCR) to harbor the *nuc* and *mec* genes. The antimicrobial susceptibility pattern was determined by the disc diffusion test using the following antibiotics: clindamycin, ciprofloxacin, gentamicin, amikacin, tetracycline, rifampicin and trimethoprim/sulfamethoxazole, in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI) [20]. Inducible macrolide-lincosamide-streptogramin B resistance (MLSb) was determined by the D-test, and the vancomycin MICs were evaluated. Once the isolates were confirmed, the infection type was classified using clinical and epidemiological information obtained from medical records. The infection type was classified as community-associated (CA), healthcare-associated infection community onset (HACO) or hospital onset (HAHO), according to standard epidemiological definitions established by the U.S. Centers for Disease Control and Prevention (CDC) [21]. The infections were classified according to the following definitions:

**CA-MRSA**: Clinical condition and isolation of MRSA without healthcare-associated risk factors.

**HACO-MRSA**: Isolation of MRSA within the first 48 hours of hospital admission and at least one of the following health care risk factors: the presence of an invasive device at the time of admission, a history of MRSA infection, surgery, hospitalization, dialysis, or intensive care unit (ICU) admission during the 12 months preceding the culture date.

**HAHO-MRSA**: Isolation of MRSA after 48 hours of hospital admission and at least one of the risk factors mentioned above [21].

**DNA isolation and SCCmec typing**

Genomic DNA was extracted from each MRSA isolate and grown in BHI broth overnight at 37°C. The bacterial pellet was suspended in 0.5 mM EDTA (pH 8) and digested with lysostaphin (2 mg/ml), lysozyme (20 mg/ml) and proteinase K (20 mg/ml). DNA was extracted and purified by alcohol precipitation with 2-propanol and ethanol. The DNA was quantified by 260/280 spectrometry and stored at −20°C.

SCCmec typing of the MRSA isolates was performed under previously described conditions to identify the five main SCCmec structures, I-V [22,23], and the SCCmec-IV subtypes were also identified [5,24]. As reference strains, COL, N315, MW2, E-MRSA-16, JCSC2172, JG1C4708, WIS, and 85/2082 were included; these strains were supplied by NARSA (Network on Antimicrobial Resistance in *S. aureus*) and the National Institute of Health in Colombia.

**Multilocus Sequence Typing (MLST)**

MLST was conducted using primers and protocols described previously [7]. Seven housekeeping gene fragments (402–516 bp) were amplified and sequenced. The sequence type (ST) was determined for each strain by comparing the sequence obtained to known alleles at each locus in the MLST database [http://saureus.mlst.net]. The STs sharing 100% genetic identity in at least five of the seven MLST loci were grouped into a clonal complex (CC), and the ancestral founders were identified using the eBURST v3 program. To identify further relationships between the isolates, a minimal spanning network of MLST data was generated using TCS v2.1.

**Polymorphism of the X region encoding protein A (spa typing)**

The X region of the *spa* gene was amplified and sequenced as described previously [25]. The sequences were analyzed with the Ridom StaphType software program (version 1.4; Ridom, GmbH, Wurzburg, Germany [http://spa.ridom.de/index.shtml]) to obtain the *spa* type for each strain.

**Accessory gene regulator (agr) typing**

To distinguish between the *agr* groups I, II, III, and IV, the *agr* gene was amplified in each MRSA isolate using the primers and conditions described by Peacock *et al.* [26]. In those reactions, the amplification of a 739-bp DNA fragment corresponded to *agr* group I, that of a 691-bp fragment corresponded to *agr* group II, that of a 712-bp fragment corresponded to *agr* group III, and that of a 683-bp fragment corresponded to *agr* group IV.

**Virulence gene profiles**

The isolates were screened for the following 13 staphylococcal virulence genes: the staphylococcal enterotoxin genes (*seb, seq, sek*), the exfoliative toxin genes (*eta, etb*), the PVL genes (*lakF/S-PV*), the gamma-hemolysin gene (*hlg*), and the adhesin genes (*fnb-A, clf-A, clf-B, ica, cna*) as previously described [26,27]. The DNA sequencing was performed to confirm the presence of *pel* genes in a subset of 5 strains carrying the SCCmec type I.
Ethics Statement

The research protocol and informed consent were approved by the Bioethics Committee at the Universidad Industrial de Santander in accordance with the ethical standards of the 1964 Declaration of Helsinki (Acta No. 15 27/08/2007). Each child’s parents or guardians provided written informed consent for the review of medical information, and all the information was confidential.

Results

Fifty-three MRSA isolates were obtained from patients 2 months to 13 years old with local or systemic infections, and all the isolates were positive for the mac and mecA genes. Most of the MRSA isolates were susceptible to the majority of the antibiotics tested; only one isolate presented a multi resistant phenotype (resistant to 4 antibiotics); 47% of the MRSA isolates exhibited resistance to tetracycline, 38% to erythromycin, 26% to ciprofloxacin, 25% to clindamycin and 2% to TMP-SMX. All the strains were susceptible to vancomycin and rifampicin.

Clinical analysis was performed in 81% of the documented infections. Among the 43 infections in which the origin was documented, 46% were CA-MRSA, 35% were HAHO-MRSA, and 19% were HACO-MRSA.

Molecular typing

Three SCCmec types were found among the isolates: type I in 15%, IVa in 4% and IVc in 75%. Three isolates were not typeable (NT) among the five SCCmec types searched for in the study (6%) (Table 1). The isolates classified as CA-MRSA and HACO-MRSA predominantly harbored the SCCmec IVc/a (80% and 88%, respectively); however, these SCCmec types were also carried in a high percentage of HAHO-MRSA isolates (74%). The SCCmec type I caused 20% of CA-MRSA cases and 20% of HAHO-MRSA cases.

Using MLST, the 53 strains of this study were grouped in eight different STs; the majority (36 isolates) were ST8 (67.9%), and nine isolates were ST5 (17%) (Table 1). The MLST data analysis by eBURST v3 grouped the isolates into one CC and four singletons. The CC was conformed for ST8 as a probable founder (Table 1). A minimal spanning network was generated to evaluate the nucleotide differences between the isolates. This methodology revealed that the strains clustered by eBURST differed by one polymorphism (Figure 1A), and the singletons differed by more than seven nucleotides.

The spa typing discriminated MRSA in twelve spa types, and two spa types were the most prevalent: t024 (56.6%) and t149 (15.1%). Two new repeat sequences were identified, and they were assigned numbers by the SpaServer (spaServer.ridom.de): t10786 (15.1%). Two new repeat sequences were identified, and they were assigned numbers by the SpaServer (spaServer.ridom.de): t10786 (15.1%).

Three agr groups were found to be the most frequent: agr group I (71.7%), followed by agr group II (11.3%) and agr group III (9.4%). Four isolates were not classified in any of the established agr groups.

The association between various molecular types was observed. The ST8 genotype was related primarily with spa t024 (25/36) and t008 (4/34) and less frequently with five spa types: t1635, t1705, t2953, t10796 and t10799. The ST5 genotype was associated primarily with spa type t149 (8/9) (Table 1).

Combining the SCCmec and MLST genotypes identified four clonal complexes (CC): CC8, CC5, CC80 and CC78 (Table 1). Seven different clones belonged to CC8 (75.5%); ST8-MRSA-IVc was the most frequent clone (60.4%). CC5 included ST5-MRSA-I (7.5%) and ST5-MRSA-IVc (7.5%). CC78 included ST80-MRSA-I (2%). Three isolates did not cluster into any of these four clone complexes because they were not typeable by SCCmec.

Correlation between molecular types and virulence genes

All the isolates were carriers of at least one toxin gene. The most prevalent toxin genes detected were hlg (100%), sek (92%), pvl (88%), seq (49%) and seh (40%) (Table 2). The tst-I gene was not detected in any of the MRSA isolates. The adhesion genes were presented in most of the MRSA isolates; 89% carried the cfr-A gene, 87% carried cfr-B, 83% carried fnb-A, and 83% carried ica (Table 2). None of the MRSA isolates carried the cna gene. Some virulence genes were associated with specific molecular types (Table 2); sek and pvl were predominantly associated with SCCmec I and SCCmec IVc; agr group I; and ST8 and ST5. In the SCCmec I pvl+ strains, DNA sequencing confirmed the presence of the pvl gene (Figure 2). The seq gene was mainly carried by the isolates with SCCmec IVc, agr group I, and ST8. The seh gene was associated with SCCmec IVc, agr group II and ST5. A total of ten virulence gene profiles were observed. The most prevalent were

| Clonal complex (CC) | MLST1 agr group | SCCmec type | spa type | No. |
|---------------------|-----------------|-------------|----------|-----|
| CC8                 | ST8             | I           | IVc      | t008 | 4  |
|                     |                 |             |          | t024 | 22 |
|                     |                 |             |          | t1705| 1  |
|                     |                 |             |          | t2953| 1  |
|                     |                 |             |          | t10796| 1 |
|                     |                 |             |          | t10799| 1 |
|                     |                 |             |          | t1635| 1  |
|                     |                 |             |          | t024 | 2  |
|                     |                 |             | NT       | t024 | 1  |
|                     |                 |             |          | NT   | 1  |
|                     |                 |             |          | t0149| 3  |
|                     |                 |             |          | t149 | 3  |
|                     |                 |             |          | t1019| 1  |
|                     |                 |             |          | t024 | 1  |
|                     |                 |             |          | t0149| 1  |
|                     |                 |             |          | t149 | 1  |
|                     |                 |             |          | t0888| 1  |
|                     |                 |             |          | t1814| 1  |
|                     |                 |             |          | t189 | 1  |
|                     |                 |             |          | t044 | 1  |

1MLST allelic profile in the order of arcC-aroE-pppF-gmk-pta-tpi-ygiL;
2New spa type (allelic profile: 11-19-12-12-34-22-24-34-22-25);
3New spa type (allelic profile: 11-15-12-15-17-34-32-34-22-25) after comparing the sequences and allelic profiles with those deposited in the spa typing website (http://spa.ridom.de/index.shtml).

doi:10.1371/journal.pone.0073434.001
Discussion

The genotypic characterization of MRSA has been widely used in epidemiological studies to understand the behavior and distribution of clones and CC and to establish and implement appropriate control measures to prevent the spread of MRSA infection. Given the strong effect of MRSA infections on pediatric patients, who have increased morbidity and mortality, it is necessary to genotype the isolates and to correlate their genotypes, phenotypes and clinical features.

In this study, ST8-MRSA-IVc was the predominant CC. In Latin America, the ST8-SCCmec-IVc clone is a variant of USA-300 referred to as USA300-LV, which has been detected previously in Colombia, Ecuador, Venezuela, Peru, Argentina and Trinidad and Tobago [17,28,29]. It is characterized by the presence of SCCmec IVc, the absence of ACME and frequent resistance to tetracycline [29]. Although SCCmec-IVc has been detected mainly in CA-MRSA clones, most of the MRSA isolates in our hospital were identified as ST8-MRSA-IVc, and only a small percentage of isolates carried the SCCmec type I. These findings confirm the establishment and high prevalence of CA-MRSA strains, particularly the USA300-LV clone, in hospitals, as previously reported [17,28].

Although the Pediatric clone has been characterized as presenting a sensitivity profile, the ST5-MRSA-IVc/a clones described in this work presented a resistance profile against non-beta lactam antibiotics, in agreement with previous reports in Colombia [16]. The isolates of the ST5-MRSA-I clone had a profile of multidrug resistance and were associated with nosocomial infections, similar to isolates described previously in Colombia and in other Latin American countries such as Chile, Argentina and Paraguay [30,31,32,33,34,35]. Although in lower percentages, the ST931-MRSA-I, ST552-MRSA-IVc, and ST80-MRSA-IVc clones were detected and are reported herein for the first time in Colombia, demonstrating the circulation of different clones in our hospital.

Based on their agr polymorphisms, the isolates were classified into four groups, I-IV. The agr group I was identified in the
majority of the analyzed isolates, as previously reported in other countries, with a predominance of this group among the clinical isolates [36,37,38]. Other studies have reported either agr group III as being predominant among CA-MRSA isolates [39] or an equitable distribution of the four agr groups [40,41]. The polymorphisms in the agr or altered expression of the agr system have been linked to the phenotype of intermediate resistance to vancomycin (VISA) and heterogeneous resistance (hetero-VISA) [40,42]. In our study, all of the MRSA isolates were susceptible to vancomycin.

Staphylococcal protein A (SpA) is anchored in the cell wall and is a virulence factor present in most S. aureus isolates [43]. The polymorphism found in region X of the gene spa has been used in the characterization of S. aureus, showing a discriminatory power comparable to other methods, such as PFGE and MLST [44]. A total of twelve spa types were found in this study, and two of them were not previously reported (t10796 and t10799). The spa t024 was more frequently associated with ST8, ST254, ST552 and ST931 (CC8), as described previously [45]. In Colombia, a previous study identified a higher frequency of t1610 and the absence of t024 [17]. The spa type t149 is one of the most common types in South America and has been related with the Cordobes/Chilean clone [34,46]. In our study, t149 was the second most common type and was associated with ST5, which was similar to the results of a previous study on HA-MRSA [34]. Other spa types identified include t189 and t1635; the latter was associated with ST8. Although Jimenez et al. also reported these spa types in Colombia, the types were related with ST188 and ST1923 [17].

The Panton-Valentine leukocidin (PVL) has been associated with the progression to severe infections such as necrotizing pneumonia, bone and joint infections and bacteremia [27,47,48,49]. A total of 75% of our isolates, most commonly

![Figure 2. Alignment of the pvl sequences detected in a MRSA isolate harboring SCCmec type I. doi:10.1371/journal.pone.0073434.g002](image)

| Table 2. Virulence gene distribution among the molecular types of MRSA isolates from pediatric patients. |
|---------------------------------------------------------------|
| **Virulence gene** | **MLST No. (%)** | **agr group No. (%)** | **SCCmec type No. (%)** | **No. (%)** |
|-------------------|-----------------|----------------------|------------------------|------------|
|                  | ST8 | ST5 | ST254 | ST80 | ST88 | ST188 | ST552 | ST931 | I | II | III | NT | Iva | IvC | NT |
| **pvl**           | 34 (71) | 7 (15) | 2 (4) | 1 (2) | 2 (4) | – | 1 (2) | 1 (2) | 35 (73) | 5 (10) | 4 (8) | 4 (8) | 7 (15) | 2 (4) | 37 (77) | 2 (4) | 48 (90) |
| **seb**           | 14 (67) | 6 (29) | 1 (5) | – | – | – | – | – | – | 13 (62) | 5 (24) | 1 (5) | 2 (10) | 5 (24) | – | 16 (76) | 6 (24) | 21 (40) |
| **seq**           | 23 (88) | 1 (4) | 2 (8) | – | – | – | – | – | – | 23 (89) | 1 (4) | – | 2 (8) | 8 (21) | 1 (4) | 22 (85) | 1 (4) | 26 (49) |
| **sek**           | 36 (73) | 7 (14) | 2 (4) | 1 (2) | – | 1 (2) | 1 (2) | 1 (2) | 37 (76) | 4 (8) | 4 (8) | 4 (8) | 7 (14) | 1 (2) | 39 (80) | 2 (4) | 49 (92) |
| **eta**           | 5 (56) | 2 (22) | – | – | 2 (22) | – | – | – | 5 (56) | 1 (11) | 1 (11) | 2 (22) | 1 (11) | 2 (22) | 4 (44) | 2 (22) | 9 (17) |
| **etb**           | – | – | 1 (100) | – | – | – | – | – | – | 1 (100) | – | – | – | – | 1 (100) | – | – | 1 (2) |
| **fnb-A**         | 29 (66) | 8 (18) | 2 (5) | 1 (2) | 2 (5) | 1 (2) | 1 (2) | – | 31 (71) | 5 (11) | 5 (11) | 3 (7) | 6 (14) | 1 (2) | 34 (77) | 3 (7) | 44 (83) |
| **clf-A**         | 33 (70) | 9 (19) | 1 (2) | 1 (2) | 1 (2) | 1 (2) | 1 (2) | – | 34 (72) | 6 (13) | 3 (7) | 2 (4) | 6 (13) | 2 (4) | 38 (81) | 1 (2) | 47 (89) |
| **clf-B**         | 33 (72) | 6 (13) | 2 (4) | – | 2 (4) | 1 (2) | 1 (2) | 1 (2) | 36 (78) | 3 (7) | 4 (9) | 3 (7) | 6 (13) | 2 (4) | 35 (76) | 3 (7) | 46 (87) |
| **ica**           | 30 (68) | 8 (18) | 2 (5) | 1 (2) | 1 (2) | 1 (2) | 1 (2) | – | 33 (75) | 5 (11) | 5 (11) | 2 (2) | 6 (14) | 2 (5) | 35 (80) | 1 (2) | 44 (83) |
the SCCmec IVc isolates, were pvl +; some of the SCCmec I and IVa isolates were also pvl +. These results are in agreement with some reports in the United States, China and Lebanon, where most MRSA carriers of SCCmec IVa and IVc are pvl+ [50,51,52]. The detection of pvl genes in SCCmec I strains is not common, and these genes have not been detected in HA-MRSA strains (SCCmec I, II or III) [53,54]. In Colombia, SCCmec I pvl+ isolates have been reported [55], although in a lower percentage than in our hospital.

*S. aureus* produces a large number of toxins including hemolysins, staphylococcal enterotoxins (SEs), exfoliative toxins (ETA and ETB) and the toxin of toxic shock syndrome-1 (TSST-1), which causes food poisoning, enterocolitis, scalded skin syndrome and toxic shock, among other conditions [56]. The majority of MRSA isolates were found to harbor the *hlg*, *sek*, *seb* and *seq* genes, but no association was found between SCCmec type and SEs genes, as described previously [38,57]. The low frequency of eta and sib coincides with the results of a study that found these genes in 5% of *S. aureus* [58]. Some isolates carried multiple toxins, and a total of ten toxin gene profiles were found in our study. The most prevalent profiles were *seq-sek-hlg*, *sek-hlg*, *seq-seq-sek-hlg* and *sek-sek-hlg*. There was a great variety of toxin combinations, but contrary to previous reports [38,57,59], no statistical association was found between toxin gene profiles with a molecular type or SCCmec type.

*S. aureus* expresses many surface proteins of the MSCRAMM (microbial surface components recognizing adhesive matrix molecules) family, which specifically recognize and bind to the extracellular matrix components of the host. Among the five adhesion molecules evaluated in this work, *clf-A*, *clf-B* and *fnb-A* were the most prevalent. The *clf-A* and *clf-B* genes encode an adhesin protein for fibrinogen and *fnb-A* for fibrinogen and fibronectin. The high percentage observed in our study is consistent with the fact that these genes are ubiquitously carried by different *S. aureus* lineages [26] and that these genes have been reported to play a determinant role in bacterial virulence [60].

The *eta* gene was not detected in any of our isolates, and although its role in the pathogenesis of bone infections is well documented, it appears to play a less determinant role in skeletal muscle infection [61].

SCCmec IVc was predominant in the isolates classified as CA-MRSA, HACO-MRSA and HAHO-MRSA. This finding confirms a high prevalence of SCCmec IVc isolates (characteristic of CA-MRSA) in Colombian hospitals and their circulation as nosocomial pathogens causing HACO-MRSA and HAHO-MRSA. Although all of the isolates were from hospitalized patients, SCCmec I was detected in a low percentage of isolates (15%) and was associated with all three infection types. All of the pediatric patients developed moderate or severe infections, predominantly skin and soft tissue infections. In some cases, the patients presented with invasive disease such as bacteremia, and in all cases, the patients had to be treated and hospitalized in an advanced level hospital. The severity of the MRSA infections observed in the pediatric patients included in the analysis might be related to the high frequency of virulence factors carried by the isolates. In previous studies, a number of genes such as *pol*, *hlg*, *fnbA*, *eta*, *sib*, *sibE*, *hlg*, *seb*, *eta* and *iva* have been associated with the development of invasive disease, contributing independently to the virulence of *S. aureus* [26,62].

We identified the presence of four CC among the MRSA isolates from pediatric patients in a hospital in Colombia. The molecular type ST3-MRSA-IVc-pvl+ was the most prevalent. New spa types were detected for the first time in Colombia, as well as two new repeat sequences: spa t10799 and t110796. Different toxin profiles were identified that showed great diversity among the isolates, and the majority of them carried one or more toxin genes. MRSA carried numerous adhesion molecules with other virulence factors such as toxins that are essential for the establishment of clinical disease with deep tissue involvement and severe progression, such as those observed in the pediatric patients of this study. We have confirmed the presence of CA-MRSA type strains (ST3-MRSA-IVc-pvl+) associated with pediatric infections in our hospital.

**Acknowledgments**

The authors thank Myriam Fanny Anaya Martínez and the entire Clinical Laboratory working group of the Hospital Universitario de Santander for their collaboration in the collection of the MRSA isolates as well as the Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARS) and the National Institute of Health of Colombia (INAS) for providing the reference strains used in this study.

**Author Contributions**

Conceived and designed the experiments: MM CIG. Performed the experiments: MM. Analyzed the data: MM LMS CIG. Contributed reagents/materials/analysis tools: LMS CIG. Wrote the paper: MM CIG.

### Table 3. Virulence gene profiles associated with different SCCmec types and *agr* groups of MRSA isolates from pediatric patients.

| Virulence gene profiles | SCCmec type | *agr* group | No. (%) |
|-------------------------|-------------|-------------|---------|
| seq-sek-hlg             | IVc         | I           | 11 (20.8) |
| seq-sek-hlg             | IVc         | NT          | 1 (1.9)  |
| seq-sek-hlg             | IVc         | II          | 9 (17)   |
| seq-sek-hlg             | I           | II          | 1 (1.9)  |
| seq-hlg                 | IVc         | I           | 7 (13)   |
| seq-hlg                 | IVc         | II          | 1 (1.9)  |
| seq-hlg                 | IVc         | III         | 1 (1.9)  |
| seq-hlg                 | I           | I           | 1 (1.9)  |
| seq-hlg                 | I           | III         | 1 (1.9)  |
| seq-hlg                 | NT          | III         | 1 (1.9)  |
| seq-hlg                 | IVc         | I           | 5 (9.4)  |
| seq-hlg                 | IVc         | NT          | 1 (1.9)  |
| seq-hlg                 | I           | II          | 1 (1.9)  |
| seq-hlg                 | I           | III         | 1 (1.9)  |
| seq-sek-eta-hlg         | IVc         | I           | 2 (3.8)  |
| seq-sek-eta-hlg         | IVa         | I           | 1 (1.9)  |
| seq-sek-eta-hlg         | NT          | NT          | 1 (1.9)  |
| seq-sek-eta-hlg         | IVc         | II          | 1 (1.9)  |
| seq-sek-eta-hlg         | I           | NT          | 1 (1.9)  |
| seq-sek-eth-hlg         | I           | I           | 1 (1.9)  |
| seq-eta-hlg             | IVc         | I           | 1 (1.9)  |
| eta-hlg                 | IVa         | III         | 1 (1.9)  |
| eta-hlg                 | NT          | I           | 1 (1.9)  |
| seq-hlg                 | IVc         | II          | 1 (1.9)  |
| Total                   |             |             | 53 (100) |

**doi:10.1371/journal.pone.0073434.t003**
References

1. Lowy FD (1998) *Staphylococcus aureus* infections. N Engl J Med 339: 509–523.
2. Arvidson S, Tegmark K (2001) Regulation of virulence determinants in *Staphylococcus aureus*. Antonie van Leeuwenhoek 80: 59–75.
3. Dersanski S, et al. (2003) Methicillin-resistant *Staphylococcus aureus*: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 36: 52–67.
4. Cosgrove SE, et al. (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible *Staphylococcus aureus* bacteremia: a meta-analysis. Clin Infect Dis 36: 53–59.
5. Kondo Y, et al. (2003) *Staphylococcus aureus* strain diverse in the United States. J Clin Microbiol 41: 108–118.
6. Erricht MC, et al. (2003) Characterization of a strain of community-associated methicillin-resistant *Staphylococcus aureus* widely disseminated in the United States. J Clin Microbiol 41: 108–118.
7. Enright MC, et al. (2003) Virulence determinants in community and hospital meticillin-resistant *Staphylococcus aureus*. J Hosp Infect 56 Suppl 2: 105–109.
8. Delco FR, et al. (2003) *Staphylococcus aureus* clones in Latin America. Int J Infect Dis 7: e566–e566.
9. Pérez D, et al. (2003) Atta referencia dos los microorganismos patógenos en el Hospital San Ignacio de Montería. Universitaria Médica 44: 298: 1763–1771.
10. Jodoño JF, Ortiz GM, Cervan AM (2006) Prevalencia de *Staphylococcus aureus* resistente a meticilina en personal de la unidad de terapia intensiva de la Clínica Universitaria Bolivariana, Medellín 2004. Asociación Colombiana de Infectología: 10: 160–166.
11. Cruz G, et al. (2006) *Staphylococcus aureus* strains colonizing children and their guardians. J Clin Microbiol 44: 192–200.
12. Lu PL, et al. (2006) Prevalence and molecular characterization of *Staphylococcus aureus* isolates carrying Panton-Valentine leucocidin genes in Colombia. Am J Infect Control 38: 315–318.
13. Sola C, et al. (2007) USA300 abroad: global spread of a virulent strain of *Staphylococcus aureus* epidemic and sporadic clones in Cordoba, Argentina. J Clin Microbiol 44: 192–200.
14. Sola C, et al. (2006) Emergence and dissemination of a community-associated methicillin-resistant *Staphylococcus aureus* clone sharing the sequence type 5 lineage with the most prevalent nosocomial clone in the same region of Argentina. J Clin Microbiol 46: 1826–1831.
15. Mayor L, et al. (2006) Prevalence and phenotype characterization of *Staphylococcus aureus* isolates from blood in Taiwan. PLoS One 7: e30394.
16. Decker P, et al. (2007) Community-acquired *Staphylococcus aureus* carriage, infection and transmission in dialysis patients, healthcare workers and their family members. Nephrol Dial Transplant 23: 1609–1620.
17. Frenay HM, Bunschoten AE, Schouls LM, van Leeuwen WV, Vandenbroucke-Grauls CM, et al. (1996) Molecular typing of *Staphylococcus aureus* strains colonizing children and their guardians. J Clin Microbiol 44: 1499–1502.
18. Palmquist N, Foster T, Torkowski A, Josephson E (2002) Protein A is a virulence factor in *Staphylococcus aureus* arthritus and septic death. Microb Pathog 33: 239–249.
children with atopic dermatitis and healthy subjects in Taiwan. Br J Dermatol 162: 1110–1116.

50. Abdel-Haq N, Al-Tatari H, Chearskul P, Salimnia H, Asmar BI, et al. (2009) Methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized children: correlation of molecular analysis with clinical presentation and antibiotic susceptibility testing (ABST) results. Eur J Clin Microbiol Infect Dis 28: 547–551.

51. Tokajian ST, Khalil PA, Jabbour D, Rizk M, Farah MJ, et al. (2010) Molecular characterization of Staphylococcus aureus in Lebanon. Epidemiol Infect 138: 707–712.

52. Wu D, Wang Q, Yang Y, Geng W, Yu S, et al. (2010) Epidemiology and molecular characteristics of community-associated methicillin-resistant and methicillin-susceptible Staphylococcus aureus from skin/soft tissue infections in a children’s hospital in Beijing, China. Diagn Microbiol Infect Dis 67: 1–8.

53. Grundmann H, Anensen DM, van den Wijngaard CC, Spratt BG, Harmen D, et al. (2010) Geographical distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Med 7: e1000215.

54. Marimon JM, Villar M, Garcia-Arenzana JM, Caba Ide L, Perez-Trallero E (2012) Molecular characterization of Staphylococcus aureus carrying the panton-valentine leucocidin genes in northern Spain. J Infect 64: 47–53.

55. Jimenez JN, Ocampo AM, Vanegas JM, Rodriguez EA, Garces CG, et al. (2011) Characterisation of virulence genes in methicillin susceptible and resistant Staphylococcus aureus isolates from a paediatric population in a university hospital of Medellin, Colombia. Mem Inst Oswaldo Cruz 106: 980–985.

56. Larkin EA, Carman RJ, Krakauer T, Stiles BG (2009) Staphylococcus aureus: the toxic presence of a pathogen extraordinary. Curr Med Chem 16: 4003–4019.

57. Wang JL, Wang JT, Chen SY, Chen YC, Chang SC (2010) Distribution of Staphylococcal cassette chromosome mec Types and correlation with comorbidity and infection type in patients with MRSA bacteremia. PLoS One 5: e9489.

58. van Trijp MJ, Melles DC, Snijders SV, Wertheim HF, Verbrugh HA, et al. (2010) Genotypes, superantigen gene profiles, and presence of exfoliative toxin genes in clinical methicillin-susceptible Staphylococcus aureus isolates. Diagn Microbiol Infect Dis 66: 222–224.

59. Becker K, Friedrich AW, Lubritz G, Weilert M, Peters G, et al. (2003) Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol 41: 1434–1439.

60. Moreillon P, Entenza JM, Francioli P, McDevitt D, Foster TJ, et al. (1995) Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 63: 4738–4743.

61. Elasri MO, Thomas JR, Skinner RA, Blevins JS, Bolen KE, et al. (2002) Staphylococcus aureus collagen adhesin contributes to the pathogenesis of osteomyelitis. Bone 30: 275–280.

62. Lim KT, Hanafiah YA, Mohd Yusof MY, Thong KL (2012) Investigation of toxin genes among methicillin-resistant Staphylococcus aureus strains isolated from a tertiary hospital in Malaysia. Trop Biomed 29: 212–219.